Abstract
With hundreds of millions of COVID-19 infections to date, a considerable portion of the population has developed or will develop long COVID. Understanding the prevalence, risk factors, and healthcare costs of long COVID can be of significant societal importance. To investigate the utility of large-scale electronic health record (EHR) data in identifying and predicting long COVID, we analyzed a sample of 1.23 million participants from the National COVID Cohort Collaborative (N3C), a longitudinal EHR data repository from 80 sites in the US with over 8 million COVID-19 patients. We characterized the prevalence of long COVID using a few different types of definitions to illustrate their relative strengths and weaknesses. Then we developed machine learning models to predict the risk of developing long COVID using demographic factors and comorbidity in the EHR. The risk factors for long COVID include patient age; sex; smoking status; and comorbidities characterized by the Charlson Comorbidity Index (CCI). We were able to predict three types of long COVID with low to moderate levels of accuracy (AUC 0.599 – 0.734). We found that age and CCI were most predictive of long COVID diagnosis. Ongoing work includes applying the fair machine learning framework to the long COVID predictive models. We are implementing fairness and bias mitigation methods to model fitting through the following steps, selecting fairness metrics, preparing data and model, evaluating fairness metrics, applying bias mitigation methods to the dataset, and comparing model results and fairness metrics before and after the mitigation. The objective is to achieve equalized odds, a statistical notion that ensures classification algorithms do not discriminate against protected groups (such as sex and race/ethnicity). Results from the fairness-based machine learning will be included in the conference presentation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by Mathematica.
N3C Attribution
The analyses described in this manuscript were conducted with data or tools accessed through the NCATS N3C Data Enclave https://covid.cd2h.org and N3C Attribution & Publication Policy v 1.2-2020-08-25b supported by NCATS Contract No. 75N95023D00001, Axle Informatics Subcontract: NCATS-P00438-B, and [insert additional funding agencies or sources and reference numbers as declared by the contributors in their form response above]. This research was possible because of the patients whose information is included within the data and the organizations (https://ncats.nih.gov/n3c/resources/data-contribution/data-transfer-agreement-signatories) and scientists who have contributed to the on-going development of this community resource [https://doi.org/10.1093/jamia/ocaa196].
Disclaimer The N3C Publication committee confirmed that this manuscript msid:1865.948 is in accordance with N3C data use and attribution policies; however, this content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the N3C program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to add a section on the assessment of algorithmic bias in the predictive model.
We also caught version inconsistencies in the previous manuscript and corrected those in this version.
Data Availability
All data produced are available online at National COVID Cohort Collaborative Data Enclave
